News

Press Release

Go to Topics

Back number

2017

Sysmex Invests in Megakaryon Corporation to Contribute to the Practical Realization of Platelet Preparations Derived from iPS Cells
Sysmex to Commence OncoBEAM™ Lab Assay Services (for Research) in Japan, as well as in Germany and the United States, to Analyze Genetic Mutations Related to Circulating Tumor DNA
Sysmex Wins Awards in 2017 Kinki Local Commendations for Inventions
Sysmex Acquires CLIA Waiver for New Automated Hematology Analyzer—The First Automated Hematology Analyzer to Receive Such Approval
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2018 (PDF:341KB)
Announcement Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ending March 31, 2018 (PDF:58KB)
Sysmex Super-Resolution Fluorescence Microscope Wins Good Design Gold Award 2017
Commencement of Collaborative Research on Measurement of Exosomes in Blood from Cancer Patients
Insurance Coverage of Lymph Node Metastasis Testing for Non-Small-Cell Lung Cancer Using the OSNA™ Method
Sysmex Signs Affiliation Agreements with Figure Skaters Mai Mihara and Kaori Sakamoto
-Supporting the Efforts of Athletes from Kobe as They Take up Challenges on the World Stage-
Sysmex Launches the Revohem FVIII Chromogenic, a Coagulation Factor VIII Assay Reagent
-Helping to Diagnose and Assist in Treatment of Hemophilia A-
Sysmex Signs Agreement with Mongolia’s Ministry of Health to Provide External Quality Assessment Support in the Field of Blood Morphology Testing
Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the Second Consecutive Year
Sysmex Begins Conducting Direct Sales and Services in Ghana
Sysmex to Commence Sales of “Revohem PT” Reagent for Measuring Prothrombin Time, a Key Testing Parameter for Monitoring Anticoagulation Therapy
-First Japanese PT Reagent Using Recombinant Protein Mass Produced by Silkworms-
Sysmex, Hyogo Pharmaceutical Society and Shinkai Transport Systems Enter Agreement to Cooperate on Disaster Relief Activities
-Creating a System for Operating Mobile Pharmacies as a Disaster Response Measure-
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2018 (PDF:725KB)
Sysmex Completes Expansion of Reagent Factory in the United States
-Reagent Production Capacity Boosted to 1.8 Times Former Level in Line with Expected Increase in Demand in the Americas-
Sysmex and bioMérieux Agreed to Dissolve the Joint Venture Sysmex bioMérieux Co., Ltd.
Our Views and Policy regarding Investment Unit Reduction (PDF:26KB)
Sysmex Expands XN-Series Product Lineup in the Hematology Field
-Achieving Further Productivity Improvements in Hematology Testing Through Footprint Reduction-
Sysmex, RIKEN GENESIS and MKI Sign Comprehensive Collaboration Agreement with a View to Joint Promotion of Genomic Medicine
Sysmex Continuing to Participate in the Global Health Innovative Technology Fund
Sysmex Opens New R&D Facility with a View toward the Realization of Personalized Medicine
Sysmex Acquires UK Company to Expand into New Business Domains toward Personalized Medicine
-Expanding Our Portfolio and Reinforcing Our Technology Base in the Life Science Business-
Sysmex Receives Invention Award in the 2017 National Commendation for Invention
Sysmex to Launch the Semi-Automated Urine Chemistry Analyzer UC-1000, a Compact Model in the Field of Urine Qualitative Analysis, in Overseas Markets
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2017 (PDF:286KB)
Sysmex Announces Changes from Financial Results Forecasts and Year-End Dividend for the Fiscal Year Ended March 31, 2017 (PDF:82KB)
Sysmex Announces New Group Mid-Term Management Plan
- Accelerating the Speed of Execution to Realize Sustainable Growth Going Forward - (PDF:119KB)
Announcement of Executive Change (PDF:53KB)
Sysmex Receives the Fiscal 2017 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology (Prize for Science and Technology)
RIKEN GENESIS Establishes RIKEN GENESIS Innovation Genome Center to Provide Lab-Assay Services for Genetic Testing
Sysmex Establishes New Company, Sysmex Harmony, to Promote the Employment of People with Disabilities
Establishment of Funded Courses at the Kobe University Graduate School of Medicine
-Encouraging Leading-Edge Cancer Research through Department of International Clinical Cancer Research-
Sysmex to Be Special Sponsor of the Kobe Marathon 2017
-We are pleased to have sponsored this exciting event since its inception in 2011-
Medicaroid Launches the SOT-100 Vercia, Operating Table with the Function to Move Patients Widely
Announcement of Organizational and Personnel Changes (PDF:449KB)
Cancer-Related Gene Panel Testing System Designated Under the Ministry of Health, Labour and Welfare’s Sakigake Designation System
FY2016 Nakatani Award and Research Grant Recipients Announced (PDF:216KB)
Sysmex Enters into Research Collaboration Agreement in Relation to Cancer and Rare Diseases with the University of Tokyo
-Aiming for the Clinical Application of Genomic Medicine-
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2017 (PDF:329KB)
Reinforcing the Sales and Service Structure in Taiwan
Transitioning to a Direct Sales and Service Structure through the Transfer of Business from a Distributor
Sysmex Selected as One of 2017 Global 100’s Most Sustainable Companies in the World